Search

everythinglearnresearchcommunity

for

Search:↓

Some common medications like metformin, insulin, and ACE inhibitors can lower PSA levels, while statins don't, and low dose finasteride significantly reduces PSA.

Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

No link found between hair loss severity and PSA levels in men.

No link between hair loss severity and PSA levels in men.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Ganoderma lucidum may help treat enlarged prostate in rats.

Finasteride works better for hair loss in patients 26 or younger.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.

Finasteride treats hair loss but may affect prostate cancer detection.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Trichoscopy helps tell different hair loss types apart using specific scalp and hair patterns.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Early balding may be a sign of future prostate problems.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.